Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
The latest update is out from Legend Biotech ( (LEGN) ).
Legend Biotech announced the availability of an updated corporate presentation at the 43rd Annual J.P. Morgan Healthcare Conference, held on January 14, 2025. The presentation highlighted the company’s leadership in CAR-T cell therapy, particularly with their product CARVYKTI®, which has shown significant success in treating multiple myeloma. With over 4,500 patients treated and substantial sales growth, CARVYKTI® continues to demonstrate a strong commercial trajectory. The collaboration with Johnson & Johnson further aims to leverage CARVYKTI’s potential in the global multiple myeloma market, positioning Legend Biotech as a key player in oncology innovation.
More about Legend Biotech
Legend Biotech is a leading biotechnology company specializing in the development of innovative cell therapies, primarily focusing on transforming cancer care. The company is a pioneer in CAR-T cell therapy, with a strong emphasis on hematologic malignancies, solid tumors, and autoimmune diseases. Legend Biotech collaborates with major pharmaceutical companies such as Johnson & Johnson and Novartis, and has established a robust pipeline supported by over 2,500 employees, including 450 dedicated to research and development.
YTD Price Performance: -6.42%
Average Trading Volume: 1,588,750
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $6.17B
For detailed information about LEGN stock, go to TipRanks’ Stock Analysis page.
